Peptide LexiconAll compounds

Defensins: The Body's Own Antibiotic Peptides, Named in 1985 and Still Not a Medicine

Defensins are small peptides, about 29 to 42 amino acids long, that the body makes to kill bacteria, fungi and some viruses. Human neutrophil defensins were named in 1985; the beta-defensins line the skin and gut. This entry covers the two human families, their structures from UniProt, what they do, and why no defensin product is approved.

Endogenous peptide familyNot a medicineNo approved product

Caroline S · Published 2026-11-16

Length

About 29–42 amino acids; three disulfide bridges each (UniProt P59665, P60022, O15263)

Sequence

HNP-1: ACYCRIPACIAGERRYGTCIYQGRLWAFCC (30) · hBD-1: DHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCK (36) · hBD-2: GIGDPVTCLKSGAICHPVFCPRRYKQIGTCGLPGTKCCKKP (41)

Origin

Alpha-defensins stored in neutrophils (Ganz 1985); beta-defensins made by epithelial cells, e.g. hBD-2 in airway and lung lining (UniProt O15263)

Last reviewed

2026-11-16

What is it good for?

Defensins are not taken as a product. They are part of the body's built-in defence: neutrophils, a type of white blood cell, store alpha-defensins in their granules, and lining cells such as those of the airways make beta-defensins. The 1985 paper that named them showed three human neutrophil defensins killing bacteria, a fungus and herpes simplex virus in the laboratory. No defensin is an approved drug.

Illustration: A coiled molecular model in white and deep green on a white surface with a subtle copper reflection.
Illustration

What they are

Defensins are small peptides the body makes to kill microbes — a built-in antibiotic system that works before antibodies are made. Human cells make two families. Alpha-defensins are packed into neutrophils, the white blood cells that swallow bacteria. Beta-defensins are made by epithelial cells: UniProt records hBD-2 in the lining of the airways and lungs and in foreskin, with lower amounts in kidney, uterus and salivary gland, and hBD-1 in blood plasma and sperm (O15263, P60022).

The name comes from the 1985 paper by Ganz, Selsted, Lehrer and colleagues in the Journal of Clinical Investigation (PMID 2997278). From a granule-rich extract of human neutrophils they isolated three small antibiotic peptides, under 3,500 in molecular weight, called them human neutrophil peptides HNP-1, -2 and -3, "which will be referred to as defensins."

Structure, family by family

All the human defensins below carry six cysteines joined in three disulfide bridges, which fold the short chain into a compact, stable shape. The sequences are UniProt's (read 2026-11-16):

Peptide Gene Length Sequence Source
HNP-1 (alpha) DEFA1 30 ACYCRIPACIAGERRYGTCIYQGRLWAFCC UniProt P59665
HNP-2 (alpha) DEFA1 29 HNP-1 without the first alanine UniProt P59665
hBD-1 (beta) DEFB1 36 DHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCK UniProt P60022
hBD-2 (beta) DEFB4A 41 GIGDPVTCLKSGAICHPVFCPRRYKQIGTCGLPGTKCCKKP UniProt O15263

HNP-1 is cut from a 94-residue precursor: a 19-residue signal piece, a 19-residue propeptide, then the chain that is trimmed to the active 30 (UniProt P59665).

The two families fold differently. Numbering the six cysteines in order, UniProt's bond positions give HNP-1 the pattern 1–6, 2–4, 3–5, and both beta-defensins the pattern 1–5, 2–4, 3–6 (our reading of the bond positions). That difference in wiring, not length, is what separates the families.

What the evidence shows

The founding paper reported that the HNP 1–3 mixture killed Staphylococcus aureus, Pseudomonas aeruginosa and Escherichia coli in a buffer containing certain nutrients, killed the fungus Cryptococcus neoformans, and directly inactivated herpes simplex virus type 1. Immunogold electron microscopy placed the peptides in the azurophil granules of the neutrophil (Ganz et al. 1985). These are laboratory findings on human cells' own peptides — not results of giving defensins to anyone.

PubMed indexes 38 randomised-trial records under the defensins heading (searched 2026-11-16); this entry did not read them all, and none has led to an approved defensin treatment. Where a study reports a change in someone's defensin level after another treatment, that level is a marker — it is not evidence that taking a defensin would help.

What is not established: that any defensin given as a medicine treats an infection in people. Natural defensins also lose activity in some conditions — the 1985 paper itself found little killing of bacteria in a nutrient-free buffer — one reason the leap from test tube to treatment is not straightforward.

Where they stand

No defensin is an approved drug; openFDA's Drugs@FDA and NDC searches for "defensin" return nothing (2026-11-16). Defensins are measured in research, and they appear in supplement and skin-care marketing as something a product "boosts" — a claim about the body's own production, which needs its own evidence. For the other major human antimicrobial peptide, see LL-37. The one approved peptide in this library designed to stop a virus, rather than a bacterium, is the HIV fusion inhibitor enfuvirtide.

Sources opened 2026-11-16: Ganz et al., J Clin Invest 1985 (PMID 2997278); UniProt P59665 (DEFA1), P60022 (DEFB1), O15263 (DEFB4A); openFDA Drugs@FDA and NDC searches; PubMed E-utilities and ClinicalTrials.gov API v2 counts.

What the research shows

Kill bacteria, fungi and some viruses

Ganz et al. 1985, J Clin Invest (PMID 2997278): HNP 1–3 from human neutrophils killed Staphylococcus aureus, Pseudomonas aeruginosa and E. coli and inactivated herpes simplex virus type 1 in vitro

Stored in neutrophil granules

Ganz et al. 1985: immunogold electron microscopy placed HNP 1–3 in the azurophil granules

Work as a treatment when given to people

No approved defensin product: openFDA returns no match for defensin in Drugs@FDA or the NDC directory (2026-11-16)

Bars show how much of the evidence is in humans, not how well anything works.

Where it stands

As a product

None approved. openFDA's Drugs@FDA and NDC searches for defensin return no record (2026-11-16).

Published record

PubMed: 1,207 records with 'defensins' in the title; 38 randomised-trial records indexed under the defensins heading. ClinicalTrials.gov: 93 studies mention defensin (2026-11-16).

Frequently asked questions

What are defensins?

Small peptides, roughly 29 to 42 amino acids long, that the body makes to kill microbes. They are part of innate immunity, the defence that works before antibodies form.

What do defensins do?

They damage bacteria, fungi and some viruses. The paper that named them in 1985 showed human neutrophil defensins killing three kinds of bacteria and a fungus and inactivating herpes simplex virus in the laboratory.

What is the difference between alpha- and beta-defensins?

Where they are made and how their cysteines pair. Alpha-defensins are stored in neutrophils; beta-defensins are made by lining (epithelial) cells, such as those of the airways. In UniProt's records the two families join their six cysteines in different patterns.

Are defensins peptides?

Yes. HNP-1 is 30 amino acids and human beta-defensin 2 is 41, each folded by three disulfide bridges into a compact shape.

Can you take defensins as a supplement or drug?

No defensin is approved as a drug, and openFDA lists no product containing one. Some supplements claim to raise the body's own defensins; that is a different claim, and it needs its own evidence.

Is LL-37 a defensin?

No. LL-37 is a human antimicrobial peptide from a different family, the cathelicidins; it is cut from a precursor called hCAP-18.